Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

RedHill Biopharma (RDHL) Other financing activities (2020)

RedHill Biopharma has reported Other financing activities over the past 1 years, most recently at $4.0 million for Q3 2020.

Quarterly Other financing activities changed N/A to $4.0 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was -$16.0 million through Dec 2020, changed N/A year-over-year, with the annual reading at $474000.0 for FY2024, 93.93% down from the prior year.
Other financing activities was $4.0 million for Q3 2020 at RedHill Biopharma, up from -$20.0 million in the prior quarter.
Over five years, Other financing activities peaked at $4.0 million in Q3 2020 and troughed at -$20.0 million in Q1 2020.